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Vitamin A (retinol) is essential for normal regulation of cell growth and differentiation. We have shown that the retinol
metabolite retinoic acid (RA) induces mucous cell differentiation of normal human tracheobronchial epithelial (NHTBE)
cells. However, early biological effects of RA in the differentiation of bronchial epithelia are largely unknown. Here, we
showed that RA rapidly activated cAMP response element-binding protein (CREB). However, RA did not use the
conventional retinoic acid receptor (RAR)/retinoid X receptor (RXR) to activate CREB. RA activated CREB in NHTBE and
H1734 cells in which RARs/RXR were silenced with small interfering RNA (siRNA) targeting RAR/RXR expression or
deactivated by antagonist. Inhibition of protein kinase C (PKC) or extracellular regulated kinase (ERK1/2) blocked the
RA-mediated activation of CREB. In addition, depletion of p90 ribosomal S6 kinase (RSK) via siRSK1/2 completely
abolished the activation, suggesting that PKC, ERK, and RSK are required for the activation. Altogether, this study
provides the first evidence that RA rapidly activates CREB transcription factor via PKC, ERK, and RSK in a retinoid
receptor-independent manner in normal bronchial epithelial cells. This noncanonical RA signaling pathway may play an
important role in mediating early biological effects in the mucociliary differentiation of bronchial epithelia.
INTRODUCTION
Vitamin A (retinol) and its related analogs, collectively
called retinoids, play a pivotal role in cell growth and dif-
ferentiation (for review, see Gudas et al., 1994). In the respi-
ratory system, retinoic acid (RA), the natural metabolite of
vitamin A, controls the development and maintenance of
differentiated mucociliary epithelial cells. It has been well
documented that RA is essential for induction and mainte-
nance of normal mucociliary airway epithelium (McDowell
et al., 1984a, 1984b). RA deficiency causes squamous meta-
plasia, and supplementation with RA restores the normal
mucous cell phenotype in cultured primary bronchial epi-
thelial cells (Koo et al., 1999). However, the early effect of RA
on mucous cell differentiation of bronchial epithelia is
largely unknown.
It has been well documented that the effects of RA at the
genomic level are mediated mainly through heterodimer-
ized forms of retinoid receptors, RARs and RXRs, which
recognize expression of their target genes through the RA
response element (A/G)G(G/T)TCA upon binding of RA
and activate gene expression (Giguere, 1994; Mangelsdorf
and Evans, 1995; Chambon, 1996). Recent data showed,
however, that RA action could be diversified to other cellu-
lar signaling pathways, the so-called nongenomic action of
RA. For example, RA has been shown to modulate PKC
activity by binding directly to PKC. RA binds directly to the
C2-domain of PKC (Ochoa et al., 2002), as determined by
structural analysis of the cocrystalized C2-domain of PKC
with RA. In addition, RA binding to the phosphatidyl serine
binding site of PKC was determined by photoaffinity la-
beling assay (Radominska-Pandya et al., 2000). It has also
been shown that retinol and its metabolites bind to the
cysteine-rich region of the regulatory domain of several PKC
isoforms, including , , , and  (Hoyos et al., 2000; Imam
et al., 2001). Therefore, we hypothesized that these diversi-
fied actions of RA may play an important role, particularly,
in triggering early events of the differentiation of bronchial
epithelia, where RA receptors are less abundant to transmit
RA action.
The transcription factor CREB plays important roles in
controlling cell growth, survival, and cell cycle progression
and in determining the fate of many cell types, including
vascular smooth muscle cells (Klemm et al., 2001), adipo-
cytes (Reusch et al., 2000), thyrocytes (Nguyen et al., 2000),
Sertoli cells (Scobey et al., 2001), and neurons (Sung et al.,
2001). Recently, it has been also demonstrated that CREB
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promotes abnormal proliferation and survival of myeloid
cells and was implicated as a proto-oncogene in myeloid
transformation (Shankar et al., 2005).
CREB is a member of the closely related CREB/CREM/
ATF family of transcription factors, recognize CRE, 5-
TGACGTCA-3, in the transcription-regulatory regions of its
target genes (for review, see Mayr and Montminy, 2001).
Recently, genome-wide analysis of the regulatory regions of
the CREB revealed numerous novel CREB target genes (Im-
pey et al., 2004). CREB was initially identified as a substrate
for protein kinase A (PKA) and has been shown to be
activated in response to various extracellular stimuli (e.g.,
hormones, growth factors, cytokines, and stress signals (for
review, see (Johannessen et al., 2004) via diverse signaling
molecules, including PKA (Gonzalez et al., 1989; Montminy
et al., 1990), PKC (Yamamoto et al., 1988), RSK (Xing et al.,
1996), mitogen- and stress-activated protein kinase 1 (Deak
et al., 1998), ERK1/2 (Fix et al., 2004), mitogen-activated
protein kinase (MAPK)-activated protein 2 kinase (Tan et al.,
1996), Akt (Du and Montminy, 1998), and calcium- and
calmodulin-dependent protein kinases II (Sun et al., 1994)
and IV (Matthews et al., 1994). These kinases phosphorylate
CREB at serine 133 residue (Yamamoto et al., 1988; Gonzalez
et al., 1989), which is required for the recruitment of CREB-
binding protein to induce CREB-mediated transactivation of
transcription.
In this study, we sought to elucidate the nonclassical
mechanisms of RA activation of the transcription factor
CREB in primary human bronchial epithelial cells. We found
that RA rapidly activates CREB in a dose- and time-depen-
dent manner and also activates ERK1/2 and RSK, a major
upstream kinase of CREB. Rapid and strong activation of
ERK1/2 and RSK is required for CREB activation. Our data
further demonstrate that RA stimulation of the CREB sig-
naling cascades does not appear to involve nuclear RA re-
ceptors.
MATERIALS AND METHODS
Cell Cultures and Chemicals
NHTBE cells (Clonetics, San Diego, CA) were cultured by air-liquid interface
method as described previously (Gray et al., 1996; Koo et al., 1999; Kolodziejski
et al., 2002). Briefly, the second passage NHTBE cells were seeded at a density
of 1  105 cells onto 24-mm semipermeable membrane inserts (Transwell-
Clear; Corning, Acton, MA) and grown in serum-free growth factor and
hormone-supplemented culture medium. Air-liquid interface was started
when the cultures were confluent. Human non-small cell lung cancer cell line
H1734 was obtained from American Type Culture Collection (Rockville, MD)
and grown in RPMI-1640 medium containing 10% fetal bovine serum (FBS).
All-trans RA (RA), 9-cis RA, 13-cis RA, retinol, cycloheximide, and actinomy-
cin D (purchased from Sigma-Aldrich, St. Louis, MO), Ro 61–8431 and Ro
26–5405 (kindly provided by Roche Bioscience, Palo Alto, CA) were dissolved
in dimethyl sulfoxide (DMSO). Other chemicals including Ro 31-8220, GF
109203X, Rottlerin, SP600125, SB203580, Y27632, U0126, 2,5-dideoxyade-
nosine, and U73122 were purchased from Calbiochem (San Diego, CA) and
were dissolved in DMSO .
Western Blot Analysis and Antibodies
Western blot analysis was performed as previously described (Song et al.,
2003). Whole-cell extracts were prepared using 2 SDS Laemmli lysis buffer.
Cytosolic and nuclear fractions were prepared according to the manufactur-
er’s instructions (Nuclear and Cytoplasmic Extraction Reagent; Pierce, Rock-
ford, IL). Equal amounts of protein (20 g) were resolved by 10% SDS-PAGE.
Antibodies used were mouse monoclonal antibodies against -actin (clone
AC-15; Sigma-Aldrich, St. Louis, MO), rabbit polyclonal antibodies against
total CREB and phospho-CREB (Ser-133 phosphorylated; Upstate Biotechnol-
ogy, Waltham, MA), rabbit polyclonal antibodies against total ERK, phospho-
ERK, p90RSK, and phospho-p90RSK (Cell Signaling Technology, Cambridge,
MA), and rabbit polyclonal antibodies against RAR, RAR, RAR, and
RXR (Santa Cruz Biotechnology, Santa Cruz, CA). Proteins reactive with
primary antibody were visualized with an horseradish peroxidase-conjugated
secondary antibody and enhanced chemiluminescence reagents (Amersham
Bioscience, Arlington Heights, IL).
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assays (EMSA) were performed as described
elsewhere (Gray et al., 2001; Aggarwal et al., 2004) with necessary modifica-
tions. Briefly, nuclear proteins (8 g) prepared from RA-treated or untreated
cells were incubated with 32P-end-labeled 21-mer double-stranded oligonu-
cleotide containing the consensus binding site for cAMP response element
(CRE) with the sequence (5-AGAGATTGCCTGACGTCAGAGAGCTAG-3)
(bold type indicates CRE; Santa Cruz Biotechnology) for 30 min at 37°C, and
the DNA-protein complex was resolved in a 6.6% native polyacrylamide gel.
For supershift analysis, nuclear extracts were incubated with 100-fold anti-
bodies against the pCREB or CREB, unlabeled probe, or CRE-mutated oligo-
nucleotide probe (5-AGAGATTGCCTGTGGTCAGAGAGCTAG-3) (bold,
CRE mutant; Santa Cruz Biotechnology) for 30 min at 37°C, and then the
complex was analyzed by EMSA. Antibodies against preimmune serum were
included as negative controls. The radioactive bands from the dried gels were
visualized and quantitated by the PhosphorImager (Molecular Dynamics,
Sunnyvale, CA) using ImageQuant software.
Immunofluorescence Analysis
NHTBE cells were fixed in a methanol:acetone mixture (1:1, vol/vol), washed
with phosphate-buffered saline (PBS), blocked with 5% preimmune serum for
30 min, and then incubated with pCREB or CREB antibody (1:100 dilution) for
2 h at room temperature. Slides were washed with PBST, incubated with
AlexaFluor 488-tagged secondary antibody (Molecular Probes, Eugene, OR)
for 1 h at room temperature and counterstained for nuclei with 4,6-dia-
midino-2-phenylindole (DAPI) for 30 min. After being washed with PBS,
slides were mounted with the SlowFade Antifade kit (Molecular Probes).
Staining for pCREB and CREB were visualized with a fluorescence micro-
scope (Axioskop 40; Carl Zeiss, Thornwood, NY), and the images were
captured at a magnification of 400 and stored using Axiovision software
(Carl Zeiss) as described in the instructions provided by the manufacturer.
Transient Transfection
NHTBE cells were plated in 24-well culture plates at a density of 1  104
cells/well. Cells were grown in BEGM without RA. When the cells reached
60–70% confluence, they were subjected to transient transfection with the
CRE-promoter-reporter construct (Stratagene, La Jolla, CA) and the -galac-
tosidase (-gal) reporter construct (BD Biosciences Clontech, Palo Alto, CA)
using a Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA) as
recommended by the manufacturer’s instructions. Briefly, The cells were
treated with a mixture of Lipofectamine reagent and plasmid DNA (0.25
g/well) for 4 h and, after transfection cells were incubated in 0.5 ml of
BEGM without RA for 24 h. Then the cultures were incubated with various
concentrations of RA (0.001, 0.01, 0.1, and 1 M), 1 M 8-Br-cAMP, or 1 M
Forskolin (positive control; Calbiochem, San Diego, CA) for another 24 h.
Cells were also transiently cotransfected with wild-type CREB (CREBwt),
mutant CREB (CREB133, S133A), or a dominant-negative CREB (KCREB)
construct along with the -gal reporter construct. After 24 h of transfection,
cells were treated with 0.1 M RA for another 24 h.
Similarly, CRE-promoter activity was measured in H1734 cancer cells using
luciferase as a reporter. Briefly, H1734 cells were seeded in 24-well tissue
culture plates (2  104 cells/well). Cells were grown in RPMI medium with
10% FBS. When the cells reached 60–70% confluence, the cells were tran-
siently cotransfected with CRE reporter construct along with -gal reporter
construct. After 4 h of transfection, the cells were incubated with medium for
24 h and then various log concentrations of RA (0.001, 0.01, 0.1, and 1 M)
were added to the medium for 24 h. Cells were subjected to lysis with 1
reporter lysis buffer (Promega, Madison, WI), and luciferase reporter and
-gal activities were determined by using a luminometer (Lumant LB 9507;
EG & Berthold, Germany).
RNA Interference
SMARTpool-sequenced small-interference RNA (siRNA) targeting human
RSK1 (Accession no. NM_002953), RSK2 (Accession no. NM_004586), RAR
(Accession no. NM_000964), RAR (Accession no. NM_000965), RAR (Ac-
cession no. NM_000966), or RXR (Accession no. NM_002957), and nonspe-
cific control pool (siRNA negative control; Dharmacon RNA Technologies,
Lafayette, CO) were diluted and stored according to the manufacturer’s
instructions. The siRNA SMARTpool used in this study contained four
pooled RNA duplexes with “UU” 3-overhangs and 5-phosphate on the
antisense strand. A mixture of several siRNAs ensured effective deletion of
the target gene in the cell. H1734 cells at 50% confluence or NHTBE cells at
60–70% confluence were transfected with a final concentration of 100 nM
SMARTpool siRNA or nonspecific control pool by using the siIMPORTER
siRNA transfection reagent (Upstate Biotechnology) according to the manu-
facturer’s instructions. The cells were treated with RA for 30 min or 24 h after
72 h of transfection, when target protein levels had been reduced by 70–80%
as assessed by Western blot analysis.
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Reverse Transcription-PCR
Total RNA was extracted using RNeasy mini-kits (Qiagen, Valencia, CA). The
reverse transcription (RT) reaction was performed using 1 g of total RNA
that was reverse-transcribed into cDNA using a random hexamer primer
(GeneAmp RNA PCR Core kit; Applied Biosystems, Foster City, CA) accord-
ing to the manufacturer’s instructions. PCR conditions were an initial 95°C for
5 min, followed by 30 cycles of 95°C, 55°C, and 68°C for 30 s each. PCR for
-actin (Ambion, Austin, TX) was done as an internal control. Primer se-
quences were as follows: RAR sense, AGCCTACGTGCCAAAAAAGG-3,
and antisense, 5-TCTAGGTGTGGAGGCAAATGG-3; and CREB sense, 5-
ACCATGGAATCTGGAGCCGAGAAC-3, and antisense; 5-CTGTAG-
GAAGGCCTCCTTGAAAGA-3. PCR products were then separated in a 2%
agarose DNA gel and stained with ethidium bromide.
RESULTS
CREB Is Activated by RA in a Time- and Dose-dependent
Manner
We used Western blot analysis to determine the time and
dose responsiveness of RA on the activation of CREB. As
shown in Figure 1A, RA induced activation of CREB in a
time-dependent manner. CREB activation was detected as
early as 15 min after RA treatment and reached a maximum
at 1 h; pCREB remained activated for 4 h thereafter. The
levels of CREB remained unchanged. It is unequivocally
clear that the RA-induced phosphorylation of CREB oc-
curred in a dose-dependent manner (Figure 1B). CREB was
activated by as little as 10 nM RA. Forskolin, a known
activator of PKA and an upstream activator of CREB, was
used as a positive control to monitor the level of comparable
activation of CREB. The levels of CREB remained un-
changed.
To determine whether transcriptional activity is involved
in the activation of CREB by RA, NHTBE cells grown in
RA-deficient medium for 7 d were preincubated with acti-
nomycin D (a general inhibitor of mRNA transcriptional
synthesis) for 2 h, followed by incubation with 1 M RA or
vehicle control for 4 h. As shown in Figure 1C, actinomycin
D had no effect on RA-induced CREB gene expression. To
determine whether new protein synthesis is required for RA
action in the CREB pathway, NHTBE cells grown in RA-
deficient medium for 7 d were preincubated with cyclohex-
imide (a general inhibitor of protein synthesis) for 2 h,
followed by incubation with 1 M RA or vehicle control for
4 h. As shown in Figure 1D, CREB expression and phos-
phorylation remained constant when protein synthesis was
blocked. Thus, these results showed that the de novo syn-
thesis of mRNA and protein is not required for the activa-
tion of CREB by RA, suggesting that RA’s action in the CREB
pathway is independent of transcriptional or translational
regulation.
RA Induces Activation of Nuclear CREB
It has been reported that CREB is translocated after activa-
tion by calcium in vascular smooth muscle cells (Stevenson
et al., 2001). To determine whether RA-activated CREB trans-
locates from the cytoplasm to the nucleus, we determined
the location of CREB and pCREB in nuclear and cytoplasmic
fractions isolated from NHTBE cells treated with 1 M RA
for 15, 30, or 60 min. As shown in Figure 1E, the majority of
CREB was localized within the nuclear fraction and that
RA-activated CREB resided in the nuclear fraction. The ac-
tivation was maximal within 15 min and continued for an-
other 60 min with no change in the level of CREB in the
nuclear fraction (Figure 1E). CREB phosphorylation and
CREB levels were much weaker in the cytoplasmic fraction
than in the nuclear fraction (Figure 1E). This result is con-
sistent with that of immunocytochemical analysis showing
Figure 1. Time- and dose-dependent activa-
tion of CREB by RA. NHTBE cells grown in
RA-deficient medium for 7 d and then treated
with 1 M RA for the indicated periods of time
(A) or with various concentrations of RA for 60
min (B). Vehicle (Ctrl) and forskolin (FC, 1 M)
were used as a negative and a positive control,
respectively. Whole-cell extracts were prepared
and subjected to Western blot analysis using
anti-CREB and anti-pCREB antibodies. To
show the effects of actinomycin D and cyclo-
heximide on the expression and activation of
CREB, NHTBE cells were preincubated for 2 h
with actinomycin D (Act. D) at 0.1 g/ml or
cycloheximide (CHX) at 5 g/ml and then in-
cubated with 1 M RA or vehicle control for
4 h. CREB expression was measured using RT-
PCR (C) and Western blot analysis (D). -actin
expression was assessed as an internal control
in RT-PCR and as a loading control for Western
blot analysis (C and D, respectively). The effect
of RA on the activation of nuclear CREB. After
NHTBE cells were treated with 1 M RA for the
indicated times, nuclear (N) and cytoplasmic
(C) extracts were prepared and subjected to
Western blot analysis using same antibodies
(E). NHTBE cells grown in RA-deficient me-
dium on cover glasses for 7 d were subjected to
immunocytofluorescence analysis (F and G).
Cells treated with vehicle (control) are shown
in the top panels, those treated with 1 M RA
for 30 min in the middle panels, and those
treated with 1 M RA for 60 min in the bottom
panels. The cells were fixed and incubated with
anti-pCREB (F) or anti-CREB (G) antibodies. The figures shown are representative of three independent experiments.
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that most of pCREB (Figure 1F) is localized in the nucleus.
RA treatment for 30 min activated CREB (Figure 1F, middle
panel), and the degree of activation was not changed by
prolonged (60 min) treatment with RA (Figure 1F, bottom
panel) compared with the untreated control (Figure 1F, top
panel). The level of CREB was the same in cells treated for 30
min as in cells treated for 60 min (Figure 1G, middle and
bottom panels). Therefore, the results unequivocally prove
that the majority of CREB is localized in the nucleus and that
RA-induced activation of nuclear CREB.
RA Activates DNA-binding Activity of CREB
To determine whether RA-activated CREB binds to the spe-
cific CRE sequence in DNA, we performed EMSA analysis
using NHTBE cells treated with different concentrations of
RA for 30 min. As shown in Figure 2A, CREB activated by
RA bound to the CRE sequence of a DNA probe in a dose-
dependent manner. The maximum binding occurred at an
RA concentration of 1 M. Moreover, CREB activated by RA
bound to the CRE sequence of the DNA probe in a time-
dependent manner, as shown in Figure 2B. The binding
occurred as early as 15 min after treatment and continued
for 2 h. Forskolin treatment was used as positive control.
Supershift analysis was used to determine whether the
retarded band visualized on EMSA in RA-treated cells was
indeed due to the binding of CREB to the specific CRE
sequence in DNA. As shown in Figure 2C, pCREB and CREB
(unpublished data) antibodies shifted the band to a higher
molecular mass, and addition of 100-fold excess of unlabeled
(cold) CRE consensus oligonucleotide caused complete dis-
appearance of the CREB band, showing that the mutant
oligonucleotides could not compete for binding. Preimmune
serum (PIS) had no effect. These results suggest that RA
activation of CREB indeed results in specific binding to the
CRE consensus DNA sequence and that most, if not all,
CREB was in a phosphorylated form in the presence of RA,
because pCREB almost completely supershifted the retarded
band.
CRE-dependent Transcriptional Activation Is Induced
by RA
RA-induced activation of CRE-dependent transcription was
determined by transient transfection of NHTBE cells with a
CRE-promoter-reporter. As shown in Figure 2D, RA in-
creased CRE promoter activity in a dose-dependent manner,
and the increase was 17-fold in cells treated with 1 M RA.
This increase in activity is as high as that induced by treat-
ment with forskolin (11-fold) or 8-Br–cAMP (20-fold), which
are known activators of CREB via PKA. The data suggest
that RA-activated CREB binds its cognate CRE site in the
promoter and induces transcriptional activity of CREB. It
has been observed that primary epithelial cells usually have
low transfection efficiency. To verify our findings in NHTBE
cells, we performed transient transfection analysis with
CRE-promoter reporter in lung cancer cell lines, H1734. As
shown in Figure 2E, RA increased CRE promoter activity in
a dose-dependent manner in the lung cancer cell lines. The
increase was 14-fold in H1734 cells at 1 M RA treatment
over that of untreated control; results were consistent with
those in NHTBE cells. Further, CRE-promoter activity after
RA treatment was 12-fold that in the control (Figure 2F).
This increase was further enhanced 19-fold by expression of
wild-type CREB, whereas RA-induced CRE promoter activ-
ity was markedly suppressed by expression of dominant
negative mutant forms of CREB, CREB133, and KCREB in
NHTBE cells. These results clearly demonstrate that CRE
transactivation by RA is dependent on CREB.
Role of RAR and RXR in Regulating Phosphorylation of
CREB and CRE-dependent Transactivation by RA
We next determined whether other types of retinoids, such
as all-trans RA, 9-cis RA, 13-cis RA, and retinol, also activate
CREB in NHTBE cells. CREB was equivalently activated
after incubation for 30 min with each of these retinoids
(Figure 3A). Of particular interest, retinol also activated
CREB as soon as 30 min after treatment (Figure 3, B and C)
and was maintained for at least 2 h in NHTBE (Figure 3B)
and H1734 (Figure 3C) cells. Thus, it is unequivocally clear
from the result that CREB activation by retinoids is not
limited to all-trans RA.
To determine whether RAR and RXR are involved in the
activation of CREB by RA, NHTBE and H1734 cells were
pretreated with 10 M Ro 61–8431 (pan-RAR antagonist) or
Figure 2. Induction of DNA-binding activation of CREB and CRE-
dependent transactivation by RA. NHTBE cells were then treated
with different concentrations of RA as indicated for 30 min (A) or
with 1 M RA for the indicated times (B). Cells used as a control
received an equivalent amount of solvent (DMSO). Vehicle (Ctrl)
and forskolin (FC) treatment cells were used as negative and posi-
tive controls, respectively. After treatment, nuclear extracts were
prepared and then assayed for CREB activation by EMSA with a
CRE consensus oligonucleotide binding probe. (C) Supershift assay.
Nuclear extracts were prepared from untreated cells and cells
treated with 1 M RA A supershift assay was performed by the
addition of anti-pCREB antibody, unlabeled CRE oligonucleotide
probe (Cold), unlabeled CRE-mutant oligonucleotide probe (Mu), or
preimmune serum (PIS). The asterisk (*) indicates shifted bands.
(D–F) Transient transfection analysis. (D) NHTBE cells were tran-
siently transfected with a CRE promoter-driven luciferase-contain-
ing plasmid. Cells were incubated with different concentrations of
RA, forskolin (1 M), or 8-Br-cAMP (1 M, as positive control) for
24 h. Cell lysates were assayed for luciferase activity. Vector control
is designated Ctrl. (E) H1734 cells were transiently transfected with
a CRE- promoter-driven luciferase-containing plasmid. NHTBE
cells were transiently cotransfected with a CRE promoter-driven
luciferase-containing plasmid and an expression vector for CREBwt,
CREB133, or KCREB and a -gal reporter construct. After transfec-
tion, cells were incubated with 1 M RA or vehicle control (Ctrl) for
24 h. Cell lysates were assayed for luciferase activity (F). The data
represent luciferase units normalized to -gal in the same cell lysate.
Data represent the mean  SE of triplicate experiments, and the
figures represent three independent experiments.
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Ro 26–5405 (pan-RXR antagonist) for 1 h and then were
incubated with RA for 30 min. Pretreatment with pan-RAR
antagonist or pan-RXR antagonist could not block RA-in-
duced CREB phosphorylation in either NHTBE or H1734
cells (Figure 3, D and E, respectively). These results indicate
that the RAR and RXR receptors were not involved in the
RA-induced CREB phosphorylation process. The activities
of pan-RAR antagonist and RXR antagonist were verified by
measuring the mRNA level of the RAR/RXR-mediated RA
target gene RAR. As shown in Figure 3, F and G, the
expression of RAR was almost completely blocked by ei-
ther antagonist. In contrast, the expression of CREB mRNA
was not changed by the antagonist treatment. This result
demonstrates the efficiency of the antagonist in inhibiting
RAR and RXR activity.
To determine whether RAR/RXR is involved in RA-in-
duced CRE-mediated transcription, transient transfection
analysis was performed using CRE-luciferase reporter. As
shown in Figure 3H, CRE-luciferase activity was induced by
RA and was not affected by the presence of pan-RAR antag-
onist or pan-RXR antagonist. It is unequivocally clear from
these results that the antagonists could not block RA-in-
duced CREB activation or CRE-mediated transcriptional ac-
tivity, strongly suggesting that RAR and RXR receptors are
not involved in RA-induced CRE transactivation.
To further confirm the role of the RAR or RXR function in
rapid activation of CREB by RA, we used the siRNA ap-
proach to deplete expression of RAR, RAR, RAR, and
RXR in NHTBE and H1734 cells. We silenced only the 
isotype of RXR because it is known that RXR plays a
dominant role in RAR/RXR heterodimers. Cotransfection of
SMARTpool-sequenced siRNA targeting human RAR and
RXR receptors with a combination of RAR/RXR, RAR/
RXR, RAR/RAR, or RAR, RAR, RAR/RXR, into
NHTBE and H1734 cells resulted in maximal silencing of the
expression of their target genes 3 d after transfection (Figure
4, A–D). Western blot analysis of RA-induced active CREB
levels after transfection by pooled RAR-, RAR-, RAR-,
and RXR-specific siRNAs revealed that RA-induced rapid
phosphorylation of CREB was not affected by depletion of
RARs and RXR in NHTBE and H1734 cells (Figure 4, A and
B, respectively). Silencing of RARs, RXR, and nonspecific
Figure 3. Retinoid receptor-independent activa-
tion of CREB by RA. (A) NHTBE cells were treated
with 1 M of all-trans RA, 9-cis RA, 13-cis RA, or
retinol for 30 min, and control cells received an
equivalent amount of solvent (DMSO). Whole-cell
extracts were prepared and subjected to Western
blot analysis using anti-pCREB and anti-CREB an-
tibodies. To show the effect of retinol on CREB
activation, NHTBE (B) and H1734 (C) cells were
treated with 1 M retinol for the indicated times.
Whole-cell extracts were prepared and subjected to
Western blot analysis using the same antibodies. To
show the effects of pan-RAR antagonist and pan-
RXR antagonist on CREB activation induced by RA,
NHTBE (D) and H1734 (E) cells were preincubated
with pan-RAR or pan-RXR antagonist (10 M) for
1 h and then incubated with RA (1 M) for 30 min.
Equal amounts of each whole-cell lysate were ana-
lyzed by Western blot using same antibodies. To
show the effects of pan-RAR antagonist and pan-
RXR antagonist on RAR mRNA expression mea-
sured by RT-PCR. NHTBE (F) and H1734 (G) cells
were preincubated with 10 M of pan-RAR antag-
onist or pan-RXR antagonist for 2 h and then incu-
bated with 1 M RA or vehicle control for 6 h. Total
RNA was used to measure RAR mRNA level.
Expression of -actin was assessed as internal con-
trols. (H) Effects of pan-RAR antagonist and pan-
RXR antagonist on RA-induced CRE-dependent
transactivation of the CRE-luciferase reporter.
NHTBE cells were transiently transfected with a
CRE promoter-driven luciferase-containing plas-
mid. Cells were incubated with 10 M pan-RAR
antagonist or pan-RXR antagonist for 2 h and then
further incubated with 1 M RA or vehicle control
for 24 h. Data represent mean  SE of triplicate
experiments and figures are a representative of
three independent experiments.
S. Aggarwal et al.
Molecular Biology of the Cell570
control pool (siRNA negative control) did not affect activa-
tion of CREB in the vehicle-treated control. This result sug-
gests that RA-induced rapid CREB activation does not re-
quire RARs/RXR. The specificity of the siRNA targeting
each receptor was verified by determining protein levels of
each receptor using the cell lysates isolated from the siRNA
transfected cells (unpublished data). Although when the
silencing of each receptor reached a maximum after 3 d,
residual amounts of RARs and RXR were still detected. To
determine the genetic effect of the residual amounts of RAR/
RXR, the expression of RAR protein was measured. As
shown in Figure 4C (NHTBE cells) and 4D (H1734 cells), the
induction of RAR expression by 24-h treatment with RA
was detected in control cells and in cells transfected with
nonspecific siRNA, but this induction was completely inhib-
ited in cells without RAR/RXR heterodimers. These results
indicate that even if there are some residual amounts of
RARs or RXR after siRNA transfection, they cannot elicit a
biological response such as induction of the expression of
the RAR/RXR target gene RAR and do not affect RA-
induced CREB activation. All these results together showed
that RA-induced activation of CREB is independent of RAR
and RXR.
Activation of CREB by RA Is Inhibited by PKC and
ERK1/2 Inhibitors
To determine which signaling pathway is involved in RA-
induced activation of CREB, we treated NHTBE cells with
various signaling inhibitors, such as Ro 31-8220, GF
109203X, and rottlerin (PKC inhibitors); Y27632 (Rock inhib-
itor); H89 (PKA inhibitor); SP600125 (JNK inhibitor);
SB203580 (p38 MAPK inhibitor); and U0126 (MEK1/2 inhib-
itor). Figure 5, A and B, shows that a 1-h preincubation of
these cells with Ro 31-8220, GF 109203X, or U0126 blocked
RA induction of CREB activation, whereas other inhibitors
did not block RA induction of CREB activation. Inhibitor
treatment alone had no effect on CREB activation. We fur-
ther demonstrated that ERK and PKC inhibitors block RA-
induced CREB activation in a dose-dependent manner (Fig-
ure 5B). However, the H-89 (a PKA inhibitor) did not have
any effect on the RA activation of CREB. To further deter-
mine the role of PKA in the activation, NHTBE cells treated
with an inhibitor of adenylate cyclase, an upstream activator
of PKA, 2,5-dideoxyadenosine (2,5-dd Ado). As shown in
Figure 5C, 25-dd Ado did not have any effect on RA-
activation of CREB, suggesting the activation is independent
of adenylate cyclase and PKA.
RA Induced Activation of CREB via MAPK Signaling
Pathway
To further determine whether the MAPK pathway is in-
volved in the RA-dependent signal transduction pathways
leading to CREB phosphorylation, we determined the acti-
vation status of ERK1/2 and RSK. As illustrated in Figure 6,
A and B, treatment with 1 M RA caused strong and rapid
increases in the amounts of phosphorylated ERK1/2, phos-
Figure 4. Effects of siRNA-mediated silenc-
ing of RAR and RXR receptor on RA-induced
CREB activation. NHTBE (A) and H1734 (B)
cells were transfected with siRNAs of RAR
and RXR in the following combinations:
siRNA of RAR and RXR; siRNA-R/X
and siRNA of RAR and RXR; siRNA-
R/X and siRNA of RAR and RXR;
siRNA-R/X and siRNA of RAR, RAR,
RAR, or RXR; siRNA-R/X; or a non-
specific control pool (NS siRNA) alone. Three
days after transfection, the cells were incu-
bated with or without RA for 30 min (A and
B) or further incubated for 24 h (C and D).
After treatment, equal amounts of whole-cell
lysates were isolated and subjected to West-
ern blot analysis using the indicated antibod-
ies (A–D). Equal loading was confirmed by
stripping the blot and reprobing it for -actin
antibody. All figures are representative of
three independent experiments.
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phorylated RSK, and phosphorylated CREB. This increase
was observed as soon as 5 min after incubation with RA, was
already maximal at 30 min, and was sustained for as long as
2 h (Figure 6A). A dose of 1 nM RA also caused increases in
the amounts of phosphorylated ERK1/2, phosphorylated
RSK, and phosphorylated CREB, but the maximal effect
occurred at a dose of 1 M (Figure 6B). In contrast, total
levels of ERK1/2, RSK, and CREB as determined with an
antibody recognizing the total proteins remained unaltered
after RA treatment.
To further determine whether the activation of ERK1/2
and RSK are dependent or not on RAR/RXR, NHTBE and
H1734 cells were pretreated with 10 M pan-RAR antago-
nist or 10 M pan-RXR antagonist for 1 h and then were
incubated with RA for 30 min. Pretreatment with pan-RAR
antagonist or pan-RXR antagonist could not block RA-in-
duced ERK, RSK, and CREB phosphorylation in either
NHTBE or H1734 cells (Figure 6, C and D, respectively).
Taken together, these results further confirmed that RA-
induced CREB activation is independent of RAR and RXR
receptor signaling.
RSK1/2 Are Indispensable for Activation of CREB by RA
To further determine whether RSK is required for the acti-
vation of CREB by RA, we used the siRNA approach to
silence expression of RSK1 and RSK2. Cotransfection into
NHTBE and H1734 cells of a pool of four SMARTpool
siRNAs that target both RSK1 and RSK2 resulted in maximal
silencing of protein expression 3 d after transfection (unpub-
lished data). As shown in Figure 7, A and B, depletion of
RSK1/2 completely abolished RA-induced activation of
CREB. Silencing of RSK1/2, however, did not affect ERK1/2
phosphorylation by RA, because ERK1/2 are upstream ki-
nases of RSK. Transfection of siRSK1/2 or siRNA negative
control did not affect CREB activation in control treatment.
These results indicate that RSK1/2, an upstream activator of
CREB, is indispensable for the activation of CREB by RA.
DISCUSSION
Our findings demonstrate nongenomic receptor-indepen-
dent RA action resulting in activation of a transcription
factor CREB in primary bronchial epithelial cells. This
genomic action of RA usually takes hours or even days.
However, our work showed that activation of CREB oc-
curred in as little as 15–30 min after RA treatment, implying
that the time frame is too short to trigger genetic activation
through transcription and translation. In fact, de novo syn-
thesis of mRNA and protein was not required for the acti-
vation of CREB by RA, suggesting that RA’s action in the
CREB pathway is independent of genomic transcriptional or
translational regulation. The rapid activation of CREB by RA
resulted in increased DNA binding of the active CREB to its
cognate CRE binding sequence. This result is in consistent
with several studies showing increased DNA binding after
CREB activation by various stimuli (Zhang et al., 2004) In
contrast, there are few reports that activation of CREB did
not lead to increased DNA binding activity in vitro (Hagi-
wara et al., 1993). Interestingly, most, if not all, of the CREB
was present in an active phosphorylated form in the pres-
ence of RA, as suggested by the finding that most of the
retarded band was supershifted by pCREB antibody.
Our data also suggest that RA activates CREB indepen-
dently of RAR/RXR, because NHTBE and H1734 cells de-
pleted of RARs/RXR by means of siRNAs targeting RAR,
RAR, RAR, and RXR could still mediate RA-induced
activation of CREB. Furthermore, selective pan-RAR and
pan-RXR antagonists did not block RA activation of CREB.
Moreover, several retinoids (9-cis-, 13-cis-, and all-trans RA)
and even retinol equivalently activated CREB rapidly in as
little as 30 min after treatment, suggesting that this action is
not limited to all-trans RA. All these results strongly suggest
that the action of RA on CREB activation is receptor inde-
pendent.
The question arises what molecule could mediate this
signaling event, if not conventional nuclear retinoid recep-
tors. Our data suggest that PKC is involved in the RA-
induced activation of CREB. Several studies provided evi-
dence that RA directly binds to PKC (Radominska-Pandya et
Figure 5. Effect of signal transduction inhibitors on RA-induced
activation of CREB. (A) NHTBE cells were preincubated with vari-
ous indicated signal transduction inhibitors (10 M) for 60 min and
then treated with 1 M RA or vehicle control for 30 min. Cells
treated as a control received an equivalent amount of solvent
(DMSO; Ctrl). (B) NHTBE cells were pre-incubated with various
indicated concentrations of signal transduction inhibitors U0126, GF
109203X, or Ro 31-8220 for 1 h and then treated with 1 M RA for
30 min. (C) NHTBE cells were preincubated with the indicated
concentration of adenylate cyclase inhibitor for 1 h and then treated
with 1 M RA for 30 min. Control cells received an equivalent
amount of solvent (DMSO; Ctrl). Whole-cell extracts were prepared
and subjected to Western blot analysis using anti-pCREB and anti-
CREB antibodies. All figures are representative of three indepen-
dent experiments.
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al., 2000; Kambhampati et al., 2003; Ochoa et al., 2003), al-
though it is somewhat controversial whether the binding of
RA to the PKC activates or inhibits PKC activity. RA acti-
vated PKC in several cancer cell lines (Kambhampati et al.,
2003) or inhibited PKC activity (Radominska-Pandya et al.,
2000). It was also reported to be biphasic, depending on the
concentration of RA used, being an activator at a low dose
and an inhibitor at a high dose (Lopez-Andreo et al., 2005).
Thus, it is apparent that the effect of RA on PKC is specific
to isotypes, cell types, and the concentration of RA. In our
primary bronchial epithelial cells, PKC activity was required
for CREB activation. However, further extensive studies are
needed to answer the question of what RA target molecule
initiates this signaling event in NHTBE cells.
ERKs, which are downstream targets of PKC, are involved
in the activation of CREB by RA in NHTBE cells. In accor-
dance with our findings, RA has been shown to activate
ERK1/2 (Yen et al., 1998, 1999) and p38 MAPK (Alsayed et
al., 2001). It was also recently reported that RA induced
activation of CREB via ERK, resulting in expression of the
c-fos gene, which does not contain RAREs but contains CRE
in its promoter (Canon et al., 2004). However, it is apparent
from our data that other MAPK, such as JNK and p38, are
not involved in RA activation of CREB. In addition, PKA,
one of the well-known CREB kinase, did not participate in
RA-mediated CREB phosphorylation.
RA activated RSK is critically required for the activation of
CREB, because omitting RSK1/2 by means of siRNAs tar-
Figure 6. Activation of ERK1/2, RSK, and CREB by
RA. NHTBE cells were cultured without RA for 7 d
and then incubated for the indicated time periods
with 1 M RA (A) or with the indicated concentration
of RA for 1 h (B). Effects of the pan-RAR or pan-RXR
antagonist on the activation of ERK1/2, RSK, and
CREB were also determined. NHTBE (C) and H1734
(D) cells were preincubated with pan-RAR or pan-
RXR antagonist (10 M) for 1 h and then incubated
with RA (1 M) for 30 min. Equal amounts of whole-
cell lysates were subjected to Western blot analysis.
Equal loading was confirmed by stripping the blot
and reprobing it for -actin antibody. All figures are
representative of three independent experiments.
Figure 7. Inhibition of RA-induced activation of CREB by siRSK.
NHTBE cells (A) and H1734 cells (B) were cotransfected with RSK1
siRNA (siRSK1), RSK2 siRNA (siRSK2) or nonspecific control pool
(NS siRNA). Three days after transfection, the cells were incubated
with and also without 1 M RA for 1 h, and then equal amounts of
whole-cell lysates were subjected to Western blot using antibodies
against using indicated antibodies. Equal loading was confirmed by
stripping the blot and reprobing it for -actin antibody. All figures
are representative of three independent experiments.
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geting RSK1/2 completely abolished the activation. It has
been shown that RSK is directly phosphorylated by ERK
(Sturgill et al., 1988; Frodin and Gammeltoft, 1999). Most of
the CREB is located in the nucleus upon stimulation by RA
without obvious translocation of CREB from the cytoplasm
to the nucleus. Therefore, activated RSKs must translocate to
the nucleus and activate CREB at Ser-133 (Ginty et al., 1994;
Xing et al., 1996). These findings are in agreement with our
recent study that showed that interleukin-1 activated CREB
through ERK/RSK1/CREB pathway in human airway epi-
thelial cells (Song et al., 2003). To the best of our knowledge,
this is the first report that RSKs are activated by RA in
primary bronchial epithelial cells.
Supporting evidence of the activation of transcription fac-
tors by RA rather than RAR/RXR has been reported re-
cently. In HL-60, RA increased binding of several transcrip-
tion factors to their respective consensus sequences (Wang
and Yen, 2004). Some of these transcription factors were
shown to be involved in the regulation of the RA target
gene, Burkitt’s lymphoma receptor, cooperatively with
RAR/RXR in HL-60 cells. However, it was not known
whether RAR/RXR are required for the activation of these
transcription factors. In our studies CREB activation by RA
in bronchial epithelial cells did not require RAR/RXR.
Although the biological significance of the receptor-inde-
pendent action of RA in normal bronchial epithelial cells
remained unresolved, particularly its significance in the
rapid activation of CREB, we speculate that RA may use
CREB (or other transcription factors) to induce early RA
response genes that do not have a classical RARE in their
regulatory region. Alternatively, RA-activated CREB may
induce genes to prepare the cells for initiation of a normal
differentiation program in which RA receptors are not suf-
ficient. In fact, we previously observed that expression of
RAR is below detectable level in RA-deficient squamous
metaplastic NHTBE cells and that RA increased RAR ex-
pression in these cells 4 h after treatment. RAR is known to
be regulated by CREB through CRE in its promoter (Kruyt et
al., 1992). Because RAR is also regulated by RAR/RXR
through RARE in the promoter of the gene, there is an
additional possibility that RA-activated CREB synergisti-
cally enhances expression of the genes required for induc-
tion of normal mucous cell differentiation. Further extensive
studies are required to prove these concepts.
Our findings can be extended to explain pathobiologic
changes in bronchial epithelia. Our preliminary observation
showed that metaplastic squamous bronchial epithelial cells
express very low levels of CREB (unpublished data). On the
other hand, inappropriate use of this nongenetic RA signal-
ing pathway may give an unfavorable growth advantage to
certain malignant cells. Retinoids may sustain CREB activity
in premalignant or malignant cells and thus promote malig-
nant cell growth. One recent study showed that CREB acts
as a proto-oncogene in leukemogenesis. Again, further stud-
ies are needed to test these speculations.
In summary, we demonstrated for the first time that RA
activates CREB through activation of the PKC, ERK, and
RSK in the absence of the influence of RAR/RXR in normal
bronchial epithelial cells. Our findings present strong evi-
dence of a function of RA in a signaling pathway quite
distinct from that of the classical retinoic acid receptor par-
adigm. Receptor-independent nonclassical action of RA in
bronchial epithelial cells can expand retinoids’ effects on
physiological processes, such as normal mucociliary differ-
entiation of bronchial epithelia. Loss or abnormal use of this
signaling pathway may cause pathobiologic changes in the
epithelia.
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